Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
Author:
Publisher
BMJ
Subject
Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy
Link
http://link.springer.com/content/pdf/10.1186/s40425-019-0513-4.pdf
Reference37 articles.
1. Eisenhauer E, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R., et al.. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer, 2009;45(2):228–247.
2. Karrison TG, Maitland ML, Stadler WM, Ratain MJ. Design of Phase II Cancer trials using a continuous endpoint of change in tumor size: application to a study of Sorafenib and Erlotinib in non–small-cell NSCLC Cancer. J Natl Cancer Inst. 2007;99(19):1455–61.
3. Jaki T, Andre V, Su TL, Whitehead J. Designing exploratory cancer trials using change in tumour size as primary endpoint. Stat Med. 2013;32(15):2544–54.
4. Suzuki C, Blomqvist L, Sundin A, Jacobsson H, Byström P, Berglund Å, et al. The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy. Ann Oncol. 2012;23(4):948–54.
5. Piessevaux H, Buyse M, Schlichting M, Van Cutsem E, Bokemeyer C, Heeger S, et al. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol. 2013;31(30):3764–75.
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Early versus late response to PD-1-based immunotherapy in metastatic melanoma;European Journal of Cancer;2024-10
2. Hierarchical cluster analysis and nonlinear mixed-effects modelling for candidate biomarker detection in preclinical models of cancer.;European Journal of Pharmaceutical Sciences;2024-06
3. Pre-treatment 18F-FDG-PET/CT parameters as biomarkers for progression free survival, best overall response and overall survival in metastatic melanoma patients undergoing first-line immunotherapy;PLOS ONE;2024-01-05
4. Clinical Impact of Early Tumour Shrinkage in Metastatic or Unresectable Oesophageal Cancer Treated with Pembrolizumab plus Chemotherapy;Oncology;2023-12-05
5. How Does Target Lesion Selection Affect RECIST? A Computer Simulation Study;Investigative Radiology;2023-11-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3